403 related articles for article (PubMed ID: 32067030)
1. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
2. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
5. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.
Armanini D; Sabbadin C; Boscaro M
J Endocrinol Invest; 2021 Sep; 44(9):2009-2010. PubMed ID: 33454931
[No Abstract] [Full Text] [Related]
6. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism.
Guo Z; Poglitsch M; Cowley D; Domenig O; McWhinney BC; Ungerer JPJ; Wolley M; Stowasser M
Hypertension; 2020 Aug; 76(2):488-496. PubMed ID: 32507039
[TBL] [Abstract][Full Text] [Related]
8. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
[TBL] [Abstract][Full Text] [Related]
9. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
10. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
11. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.
Armanini D; Scaroni C; Mattarello MJ; Fiore C; Albiger N; Sartorato P
J Endocrinol Invest; 2005 Mar; 28(3):236-40. PubMed ID: 15952408
[TBL] [Abstract][Full Text] [Related]
13. Comparison between screening for primary aldosteronism with and without drug adjustment.
Hua Y; He Q
Blood Press; 2024 May; 33(1):2350981. PubMed ID: 38824645
[TBL] [Abstract][Full Text] [Related]
14. Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study).
Sezai A; Osaka S; Yaoita H; Arimoto M; Hata H; Shiono M; Sakino H
Ann Thorac Cardiovasc Surg; 2016 Jun; 22(3):161-7. PubMed ID: 27086671
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients.
Ichikawa S; Takayama Y
Hypertens Res; 2001 Nov; 24(6):641-6. PubMed ID: 11768722
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
Pilz S; Trummer C; Verheyen N; Schwetz V; Pandis M; Aberer F; Grübler MR; Meinitzer A; Bachmann A; Voelkl J; Alesutan I; Catena C; Sechi LA; März W; Obermayer-Pietsch B; Tomaschitz A
Horm Metab Res; 2018 May; 50(5):375-382. PubMed ID: 29723896
[TBL] [Abstract][Full Text] [Related]
17. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
18. Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients.
Guasti L; Gaudio G; Lupi A; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Sarzani R; Vanasia M; Maffioli P; Derosa G
Drug Des Devel Ther; 2017; 11():2293-2300. PubMed ID: 28831241
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
[TBL] [Abstract][Full Text] [Related]
20. Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Sezai A; Soma M; Hata M; Yoshitake I; Unosawa S; Wakui S; Shiono M
Ann Thorac Cardiovasc Surg; 2011; 17(5):487-93. PubMed ID: 21881353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
